Zacks Investment Research cut shares of Pharma Mar (NASDAQ:PHMMF) from a buy rating to a sell rating in a research note released on Saturday.
According to Zacks, “Pharma Mar SA is a biopharmaceutical company. It engaged in the discovery and development of marine-derived anticancer drugs. The company’s product pipeline consists of PM1183, plitidepsin, and PM184 which are in clinical trial stage. It operates primarily in Germany, Italy, France, Switzerland, United Kingdom, Belgium and the United States. Pharma Mar SA is headquartered in Madrid, Spain. “
Shares of Pharma Mar (NASDAQ:PHMMF) traded down 5.63% on Friday, reaching $3.35. 22,600 shares of the company traded hands. Pharma Mar has a one year low of $2.40 and a one year high of $4.80. The firm’s 50 day moving average is $3.87 and its 200 day moving average is $4.20. The company’s market capitalization is $831.14 million.
COPYRIGHT VIOLATION NOTICE: “Pharma Mar (PHMMF) Downgraded to “Sell” at Zacks Investment Research” was originally posted by Community Financial News and is the property of of Community Financial News. If you are accessing this news story on another publication, it was illegally stolen and republished in violation of United States and international copyright and trademark laws. The correct version of this news story can be viewed at https://www.com-unik.info/2017/10/29/pharma-mar-phmmf-downgraded-to-sell-at-zacks-investment-research.html.
What are top analysts saying about Pharma Mar? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Pharma Mar and related companies.